文献速递胸部肿瘤

非小细胞肺癌手术切除标本与配对组织芯片中22C3 PD-L1表达的比较

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-07-24

本研究比较了190例非小细胞肺癌手术切除标本与配对组织芯片(TMA)的22C3 PD-L1表达。按TPS分组后,配对样本不一致率为18.9%(κ=0.630),TMA低估和高估分别占52.8%和47.2%。TPS<1%病例不一致率(18.4%)显著低于TPS 1%-49%(56.7%)和TPS≥50%(43.3%)(p<0.001);以TPS≥50%为界时,TPS<50%的不一致率降至7.5%。

要点

  • TMA与手术标本PD-L1 TPS不一致率18.9%,κ=0.630,中等一致。
  • TPS<1%病例不一致率18.4%,显著低于TPS 1%-49%的56.7%和TPS≥50%的43.3%(p<0.001)。
  • 以TPS≥50%为界时,TPS<50%的不一致率降至7.5%。

核心结论

  • TMA中PD-L1表达与对应手术标本中等一致,提示在诊断活检标本中评估PD-L1可能误导对帕博利珠单抗敏感性的判断,但可能可靠地排除TPS<50%的患者接受一线帕博利珠单抗治疗。

研究设计与样本

  • 对190例存档手术切除的非小细胞肺癌标本行22C3免疫组化检测PD-L1表达,并与配对组织芯片结果比较。
  • PD-L1表达以肿瘤比例评分(TPS)判定,分为TPS<1%、TPS 1%-49%和TPS≥50%三类,采用一致性统计。

主要发现

  • 190例中36例(18.9%)PD-L1 TPS不一致,配对样本间κ值为0.630。
  • 36例不一致中,TMA低估19例(52.8%),高估17例(47.2%)(p=0.118)。
  • TPS<1%病例不一致率为18.4%,TPS 1%-49%为56.7%,TPS≥50%为43.3%(p<0.001)。
  • 以TPS≥50%为界时,TPS<50%的不一致率降至7.5%。
  • 不一致主要源于PD-L1表达的瘤内异质性,与临床病理特征无显著关联。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The extent to which intratumoral heterogeneity of programmed death ligand 1 (PD-L1) expression causes discordance of PD-L1 expression between paired samples remains unclear. Here, PD-L1 status was compared between whole sections from NSCLCs and the corresponding tissue microarrays (TMAs) serving as surrogate biopsy specimens. METHODS: PD-L1 expression was evaluated by 22C3 immunohistochemistry assay on 190 archival surgical specimens and matched to the TMA results. PD-L1 expression was determined by the tumor proportion score (TPS) and classified as TPS lower than 1%, TPS of 1% to 49%, and TPS of 50% or higher. Agreement statistics were used. RESULTS: The percentage of PD-L1 expression on tumor cells differed greatly between individual TMAs and matched surgical specimens. When PD-L1 TPS was adopted, a total of 36 of 190 discordance cases (18.9%) were observed, with a κ-value of 0.630 between paired samples. The TMAs underestimated or overestimated PD-L1 status in 19 of 36 (52.8%) and 17 of 36 (47.2%) of the matched surgical specimens, respectively (p = 0.118). The discordance rate was much lower in cases with a PD-L1 TPS lower than 1% compared with in cases with a TPS of 1% to 49% and TPS of 50% or higher (18.4% versus 56.7% and 43.3%, p < 0.001). When a TPS of 50% or higher was used as the cutoff, the discordance rate of PD-L1 TPS less than 50% was further reduced to 7.5%. Such discrepancies were due mainly to intratumoral heterogeneity of PD-L1 expression and nonsignificant association with clinicopathological features. CONCLUSIONS: PD-L1 expression in TMAs correlates moderately well with that in the corresponding surgical specimens, indicating that evaluating PD-L1 expression in diagnostic biopsy specimens could be misleading in defining sensitivity to pembrolizumab treatment yet may be reliable as a way to exclude patients with a PD-L1 TPS less than 50% from first-line pembrolizumab treatment.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Li C, Huang C, Mok TS, et al. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28751245. doi:10.1016/j.jtho.2017.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。